Clinical Trials · NCT07724340
A Study to Assess the Efficacy, Safety and Tolerability of AT673 Co-administered With Semaglutide in Adult Participants With Type 2 Diabetes (T2D) and Overweight or Obesity
- Phase
- Phase 2
- Recruitment status
- Recruiting
- Sponsor
- Antag Therapeutics
- Enrollment
- 150
- Start date
- Jun 2026
- Locations
- 8 sites, United States
- Primary endpoint
- Body weight